Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma

CONCLUSION: These data support selpercatinib as an effective therapy against RET-mutant pheochromocytoma, adding to the diversity of RET-activated tumor types that may benefit from targeted RET inhibition.PMID:38661071 | DOI:10.1210/clinem/dgae283

Source: The Journal of Clinical Endocrinology and Metabolism - April 25, 2024 Category: Endocrinology Authors: Barbara Deschler-Baier Bhavana Konda Erminia Massarelli Mimi I Hu Lori J Wirth Xiaojian Xu Jennifer Wright Roderick J Clifton-Bligh Source Type: research